XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the three months ended March 31, 2022 is as follows:
(number of shares in millions)Number
of
Shares		Weighted
Average
Exercise
Price
Options outstanding at December 31, 20211.4 $20.36 
Less:
Options exercised— $23.98 
Options canceled or expired(0.1)$24.24 
Options outstanding at March 31, 20221.3 $20.17 
Options exercisable at March 31, 20220.9 $22.99 
Schedule of Restricted Stock Unit Activity
A summary of the RSU awards activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March 31, 2022 is as follows:
(number of shares in millions)Number
of
Shares		Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20213.1 $24.96 
RSUs granted1.6 $27.17 
Less:
RSUs vested(0.4)$28.24 
RSUs canceled(0.1)$24.26 
RSUs outstanding at March 31, 20224.2 $25.43 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
March 31,
(in millions)20222021
Cost of molecular diagnostic testing$0.3 $0.3 
Cost of pharmaceutical and clinical services— 0.1 
Research and development expense2.4 1.5 
Selling, general, and administrative expense7.4 7.1 
     Total stock-based compensation expense$10.1 $9.0